Brief: European Commission Approved Subcutaneous Darzalex (Daratumumab) Based Quadruplet Regimen
09/04/2025 14:10
April 9 (Reuters) - Halozyme Therapeutics Inc HALO.O: EUROPEAN COMMISSION APPROVED SUBCUTANEOUS DARZALEX® (DARATUMUMAB)-BASED QUADRUPLET REGIMEN FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA, REGARDLESS OF TRANSPLANT ELIGIBILITY Source text: ID:nPn565wxsa Further company coverage: HALO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets